A phase II peri-operative study of pembrolizumab plus lenvatinib for mucosal melanoma

Journal:: Nature Communications
Published:: 2026-05-16
DOI:: 10.1038/s41467-026-73190-1
Affiliations:: 6
Authors:: 26

Go to article

Institutions	Authors	Share
Beijing Cancer Hospital / School of Oncology, PKUHSC, China	25.000000 25.000000 25.000000	0.96
Geneplus, China	1.000000	0.04

Interested in Oncology and Carcinogenesis?

Research leaders

2026 Research Leaders

The Nature Index 2026 Research Leaders reveal the leading institutions and countries/territories in the natural sciences, health sciences, applied sciences and social sciences, according to their output in Nature Index journals in 2025.

Access free

Latest supplement

Nature Index 2026 Nanoscience and nanotechnology

From programmable RNA architectures to next-generation materials for energy and healthcare, researchers are harnessing the unusual properties of the nanoscale to tackle some of society's biggest challenges. This supplement explores the discoveries that are driving the field, the hurdles that remain and the institutions that are leading in nanoscience and nanotechnology research.

Access free

Nature Index 2026 Chemistry

Chemistry research is undergoing a period of transformation, driven by new technologies and mounting environmental pressures. In this supplement, we explore the trends behind China’s extraordinary rise in chemistry output, and why efforts to curb the use of PFASs are accelerating worldwide. We also look at the innovations that could redefine how chemicals are designed, produced and recycled.

Access free

Research highlights of partners

Why cancer cells need a sugar fix

Southern University of Science and Technology (SUSTech)
26 Dec 2023
New effect of viruses on brains discovered

The University of Queensland (UQ)
30 Nov 2023
The brain region responsible for recognizing others

Institute for Basic Science (IBS)
31 Oct 2023

Research highlights